Načítá se...

ACTR-41. INTERIM RESULTS OF FIRST-IN-HUMAN STUDY USING NATIVIS VOYAGER™ SYSTEM IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)

BACKGROUND: The Nativis Voyager® ulRFE™ system, a non-invasive investigational device, was studied in a first-in-human feasibility study to assess safety and feasibility of the treatment for recurrent glioblastoma (GBM). The anti-mitotic therapy delivers ultra-low radio frequency energy (ulRFE) prod...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Barkhoudarian, Garni, Cobbs, Charles, McClay, Edward, Vaillant, Brian, Duic, J Paul, Nabors, Burt, Ellingson, Benjamin, Sheffield, Deborah, Kesari, Santosh
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2017
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693000/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.032
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!